This a single center, randomized controlled trial to evaluate safety \& efficacy of topical nitric oxide releasing sinus irrigation (NOSi) as compared to budesonide-Saline (Control) in the management of biofilm-associated recalcitrant chronic rhinosinusitis (RCRS). It is hypothesized that a daily treatment of NOSi over a 6-week period will be safe and effective at reducing clinical symptoms associated with RCRS.
This is a prospective, single center, Phase 2, double-blinded, randomized, controlled, parallel group trial study. Up to fifty-four (54) participants will be enrolled (based on power analysis based on outcomes from a previous dose-tolerance study. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study and randomized in to the Investigational Medicinal Product (IMP) or Non Investigational Medicinal Product (NIMP) at a 2:1 ratio (NOSi:Budesonide). Each participant will be managed as an outpatient for the 42 days of the study. Participants will be administered NOSi or budesonide in saline by self-administration, at home, as a sinus irrigation to their nasopharynx and sinuses once a day. Participants will be asked to return to the clinic for evaluations on Day 21(±2), Day 43(±2) and Day 63 (±2) following the start of study interventions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
56
in situ 240mL nitric oxide releasing sinus irrigation solution
Saline based sinus irrigation 1mg Budesinide solution
St. Paul's Hospital
Vancouver, British Columbia, Canada
To assess the efficacy of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis (RCRS) as measured by the Sino-Nasal Outcome Test (SNOT-22)
Proportion of participants experiencing a 9-point reduction in Sino-Nasal Outcome test (SNOT-22) score (0-5 scale of 22 parameters with a total maxmimum score of 110 and an increased value representing worsening of condition)
Time frame: 42 days
To assess the safety of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis
Severity and frequency of adverse events as well as clinically significant Changes in laboratory findings, vital signs, histology, olfaction, and methemoglobin levels.
Time frame: 63 days
To evaluate the efficacy of NOSi compared to Budesonide on the reduction of Modified Lund-Kennedy Scores (MLK)
Mean change in MLK score as compared to control (Scale of 0-2 for 6 locations on each side (maximum total score 24); increase represents worsening
Time frame: Days 21, 42, 63
To evaluate the efficacy of NOSi compared to Budesonide on quality of life improvements (EQ-5D-5L);
Mean change in EQ-5D-5L index score as compared to control (Scale 0-100; increase indicates worsening)
Time frame: Days 21, 42, 63
To evaluate the efficacy of NOSi compared to Budesonide on the density of pathogens
Mean change in pathogen density compared to control; (log10 cfu/g)
Time frame: Days 21, 42, 63
To evaluate the efficacy of NOSi compared to Budesonide on cilia functionality
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Proportion of participants with functional cilia which is known to be denuded by biofilm as determined by the saccharin test compared to control
Time frame: Days 43 & 63
To evaluate the efficacy of NOSi compared to Budesonide on biofilm elimination
Proportion of participants with biofilm elimination compared to control
Time frame: Days 43 & 63